BETFIRSO
「BETFIRSO」对应一条老挝商标公开记录,由 Constellation Pharmaceuticals, Inc. 于 2024-08-23 提交申请,当前状态为已注册。公开档案中可核验:申请号 M/1758004,注册/授权号 64379,DIP 编号 LAM1758004,主管局代码 LA,申请类型 Other。时间线要点:公开/公告日 2024-10-24;注册日 2025-05-19。商品/服务类别(Nice)标注为 5。商品与服务说明摘录:Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of blo…。代理机构 / 代理人记载为 Novartis Pharma AG, Trademark Department。您可在站内继续浏览同申请人其它知识产权,或经企业详情查看更多关联资产与登记信息。
LaoBiz profiles the Laos trademark “BETFIRSO” from open registry fields, filed by Constellation Pharmaceuticals, Inc. on 2024-08-23; current status: Registered. Identifiers include application No. M/1758004; registration/grant No. 64379; DIP id LAM1758004; application type Other. Key dates: publication 2024-10-24; registration 2025-05-19. Nice class(es): 5. Goods/services excerpt: Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of blo…. Use LaoBiz to hop between this IP record, related filings by the same applicant, and the matched company profile when present.
ກ່ຽວກັບ ເຄື່ອງໝາຍການຄ້າ «BETFIRSO» ໃນລາວ, ຍື່ນໂດຍ Constellation Pharmaceuticals, Inc. ໃນວັນທີ 2024-08-23; ສະຖານະ ຈົດທະບຽນແລ້ວ. ຕົວລະບຸ: ເລກທີຄຳຮ້ອງ M/1758004; ເລກທະບຽນ 64379; ລະຫັດ DIP LAM1758004. ວັນທີສຳຄັນ: ວັນເຜີຍແຜ່ 2024-10-24; ວັນຈົດທະບຽນ/ອະນຸຍາດ 2025-05-19. ປະເພດ/ຫ້ອງ: 5. ສິນຄ້າ/ບໍລິການ: Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of blo…. ຂໍ້ມູນເພື່ອອ້າງອີງເທົ່ານັ້ນ ບໍ່ແມ່ນຄຳແນະນຳທາງກົດໝາຍ ຫຼື ໃບຢັ້ງຢືນສິດ.
M/1758004
图样
基础信息
- 类型
- 商标
- 申请号
M/1758004- 状态
- 已注册
- 申请人
- Constellation Pharmaceuticals, Inc.
- 代理机构
- Novartis Pharma AG, Trademark Department
- 申请日期
- 2024-08-23
- 注册号
64379- 公开/公告日
- 2024-10-24
- 注册/授权日
- 2025-05-19
- 国际分类
- 5
- 商品 / 服务
- [5] Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of blood diseases; pharmaceutical preparations for the treatment of diseases of the bone marrow; pharmaceutical preparations for the treatment of cancer, namely, BET protein inhibitors; pharmaceutical preparations for the treatment of myelofibrosis; pharmaceutical preparation for the treatment of myelodysplastic syndrome (MDS); pharmaceutical preparations for the treatment of myeloproliferative neoplasm; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for the treatment of thrombocythemia; pharmaceutical preparations for the treatment of diseases that involve dysregulation of epigenetic pathways; pharmaceutical preparations for epigenetic modulators as therapeutics; pharmaceuticals comprising small molecules; small molecule compounds for medical use and drug delivery; small molecule pharmaceuticals for the treatment of diseases and conditions; pharmaceuticals and pharmaceutical preparations for human use for the treatment and prevention of diseases and disorders; antibodies sold as a component ingredient of pharmaceuticals; diagnostic preparations for medical purposes; biological substances for human medical diagnostics and analysis; clinical medical reagents; biological preparations for medical purposes; pharmaceutical and veterinary preparations, agents and substances.
办理流程
根据当前状态动态标注-
提交申请
-
形式审查
-
实质审查
-
公告
-
注册